LK
ADAP

Lumbard & Kellner’s Adaptimmune Therapeutics ADAP Stock Holding History

Lumbard & Kellner’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-114,264
Closed -$14.9K – 101
2025
Q3 		$14.9K Buy
+114,264
New +$15.7K 0.01% 97

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Lumbard & Kellner's ADAP Position: Q4 2025 in Review

Lumbard & Kellner sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 114,264 shares — an estimated $14.9K sold.

Lumbard & Kellner first reported a position in ADAP in Q3 2025 and held it in 1 quarter. The position peaked at $14.9K in Q3 2025. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Lumbard & Kellner reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lumbard & Kellner sold 114,264 Adaptimmune Therapeutics shares in Q4 2025, an estimated $14.9K.
  • Lumbard & Kellner first reported a position in Adaptimmune Therapeutics in Q3 2025 and held it in 1 quarter.
  • Lumbard & Kellner's Adaptimmune Therapeutics position peaked at $14.9K in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Lumbard & Kellner's 13F filing for Q4 2025, filed 3 Feb 2026.